ERBB2 and breast cancer: Moreover, OncoRibo-68 score varied substantially by breast cancer subtype—with particularly high levels in the more aggressive HER2+ and Basal subtypes—and by Nottingham histological grade (G1 vs. G2 vs. G3), suggesting that upregulated RiBi might underlie more advanced tumor phenotypes (Figure 4D,E).